Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy
Interventions: JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Subjects
Interventions: placebo, lorazepam, GW876008; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy
Interventions: Selpercatinib, Moxifloxacin, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: AZD8683, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis, Chronic Obstructive Pulmonary Disease
Interventions: GS-5737; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: PF-06835919, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: AV-1, Placebo; Drug
Lead sponsor: AbViro LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Psoriasis
Interventions: CNTO 1959; Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Miramar, Florida + 5 more

Conditions: IPF
Interventions: HNC1058 Capsules; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia or Schizoaffective Disorder
Interventions: AMG 581, Placebo, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: E2730, E2730-matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Coronary Artery Disease
Interventions: RespirAct; Device
Lead sponsor: Indiana University; Other
Eligibility: 45 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Interventions: RN0361; Drug
Lead sponsor: Ikaria Bioscience Pty Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Tamarac, Florida • Versailles, Kentucky • Dilworth, Minnesota + 3 more

Conditions: Gastroenteritis Escherichia Coli
Interventions: Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, Testosterone, Buspirone hydrochloride; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: San Diego, California • Bradenton, Florida • North Miami, Florida + 9 more

Conditions: Healthy
Interventions: TT-01025-CL; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy
Interventions: Schedule A, Schedule B, Schedule C, Schedule D, Schedule E; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions: LFF269, Placebo to LFF269; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Safety
Interventions: PRV-3279 or placebo; Biological
Lead sponsor: Provention Bio, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: E2027, E2027 matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteer Subjects
Interventions: Trehalose for IV Infusion, Saline 0.9% IV; Drug
Lead sponsor: Bioblast Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, 0.5 mgTestosterone + 10 mg Buspirone; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more

Conditions: Health Adult Subjects, Obesity & Overweight
Interventions: TIX100, Placebo; Drug
Lead sponsor: TIXiMED, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Search by objective public record fields.

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

AZD8683 Single Ascending Dose Study

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

Needle Free Assessment of Myocardial Oxygenation in Healthy Subjects

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects